Medical News

RSS

Encorium announces extension of expiration date for pending rights offering

Encorium Group, Inc. , a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has extended the expiration date for its pending rights offering from September 30, 2010 to October 15, 2010. The subscription rights may now be exercised at any time prior to 5:00 p.m. ET on Friday, October 15, 2010.

1 Oct 2010

Siblings of children with autism have language delays: Study

Siblings of children with autism have more frequent language delays and other subtle characteristics of the disorder than previously understood. Girls also may be mildly affected more often than recognized in the past.

1 Oct 2010

Activating rearrangements in receptor genes are more common than previously thought

A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,--an MSKCC surgeon, researcher and the Director of the Brain Tumor Center--and was published in the October 1 issue of the journal Genes & Development.

1 Oct 2010

Vibrant joins Bike MS NYC to raise money for National Multiple Sclerosis Society

Vibrant will participate in Bike MS NYC on Sunday, October 3 to increase awareness of Multiple Sclerosis and to raise money for the National Multiple Sclerosis Society. The race, hosted by the Southern NY Chapter of the National Multiple Sclerosis Society, will include nearly 6,000 cyclists across two Bike MS NYC locations.

1 Oct 2010

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with U.S. Senator Kay Hagan (D-NC) and U.S. Congressman David Price (D-NC), are holding an official groundbreaking ceremony this morning for its U.S. plant-based commercial grade vaccine facility in Research Triangle Park, North Carolina.

1 Oct 2010

QRxPharma's A$14 million Placement oversubscribed

QRxPharma Limited has today announced a Placement which raised A$14 million and which was significantly oversubscribed.

1 Oct 2010

VirtualScopics third-quarter revenues increase 25% to $3.5 million

VirtualScopics, Inc., a provider of quantitative imaging for clinical trials, today announced revenues for the third quarter ended September 30, 2010 exceeded $3.5 million, representing a greater than 25% increase over the comparable period in 2009 and a greater than 9% growth over the preceding quarter ended June 30, 2010. Year-to-date revenues increased over 30% for the period ended September 30, 2010 compared to the same period in 2009.

1 Oct 2010

Elekta releases Atlas-based Autosegmentation 2.0 software for increasing contouring accuracy

Elekta recently launched ABAS (Atlas-based Autosegmentation) 2.0 software, which includes the Simultaneous Truth and Performance Level Estimation (STAPLE) algorithm to increase contouring accuracy. ABAS—considered the industry gold standard for autosegmentation accuracy—deforms atlases of anatomy previously defined on a reference image onto a new patient image, creating a new structure set fit to the patient anatomy and enhancing planning efficiency.

From Elekta 1 Oct 2010

Noven acquires global rights to Daytrana from Shire affiliates

Noven Pharmaceuticals, Inc. today announced that it has completed the acquisition of global rights to Daytrana® (methylphenidate transdermal system) from affiliates of Shire plc.

1 Oct 2010

The Carlyle Group announces completion of NBTY acquisition

Global alternative asset manager The Carlyle Group and NBTY, Inc., a leading global manufacturer and marketer of nutritional supplements, today announced that Carlyle has completed its $4 billion acquisition of NBTY.

1 Oct 2010

Collagen Matrix's new Collagen Dental Membrane granted FDA 510(k) clearance

Collagen Matrix, Inc., the leader in collagen- and mineral-based matrix engineering, announced today that it has received FDA's 510(k) clearance of a new Collagen Dental Membrane derived from porcine dermis indicated for use in oral surgical procedures involving guided tissue and bone regeneration.

1 Oct 2010

After McDonald's flap, White House says it will exercise 'discretion' on medical loss ratios

The Wall Street Journal: The Obama administration said Thursday that Health and Human Services Secretary Kathleen Sebelius will "exercise her discretion" in enforcing the medical loss ratio requirement of the health law. The comment comes after a report in The Journal Thursday that "McDonald's warned federal regulators it could drop its health-insurance plan for nearly 30,000 restaurant workers unless regulators waive a new requirement of the health overhaul.

1 Oct 2010

LSUHSC-S receives $3.9M NIDA grant to develop EMB-001 drug for cocaine dependence

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera's drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing.

1 Oct 2010

USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Orion's Stalevo® tablets.

1 Oct 2010

AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system

AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.

1 Oct 2010

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

In just 21 days, CVS/pharmacy's ninth annual in-store fundraising campaign to support the fight against amyotrophic lateral sclerosis (ALS) brought in $4.1 million. The funds raised by the campaign will be donated to the Boston-based ALS Therapy Alliance (ATA) to support the funding of new clinical research aimed at developing new therapies for ALS patients and focused on the ultimate goal of finding a cure for ALS.

1 Oct 2010

MedQuist enters into definitive agreements for $310 million financing

MedQuist Inc., a leading provider of integrated clinical documentation solutions for the U.S. healthcare industry, announced today that it has entered into definitive agreements relating to a $310 million financing consisting of a $225 million senior secured credit facility and the issuance of $85 million of senior subordinated notes.

1 Oct 2010

Benicar better than Cozaar in reducing blood pressure: Study

New study results show that patients treated with Benicar® (olmesartan medoxomil) 40 mg once daily had significantly greater reductions in blood pressure and higher rates of goal attainment than patients receiving Cozaar® (losartan potassium) 100 mg once daily at week 8, according to findings of a new head-to-head study presented today at the late breaker session at the 23rd Scientific Meeting of the International Society of Hypertension (ISH) in Vancouver, Canada.

1 Oct 2010

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

Chelsea prices common stock public offering

Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and commissions and expenses, will be approximately $32.8 million.

1 Oct 2010

Medical News

Encorium announces extension of expiration date for pending rights offering

Siblings of children with autism have language delays: Study

Activating rearrangements in receptor genes are more common than previously thought

Vibrant joins Bike MS NYC to raise money for National Multiple Sclerosis Society

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

QRxPharma's A$14 million Placement oversubscribed

VirtualScopics third-quarter revenues increase 25% to $3.5 million

Elekta releases Atlas-based Autosegmentation 2.0 software for increasing contouring accuracy

Noven acquires global rights to Daytrana from Shire affiliates

The Carlyle Group announces completion of NBTY acquisition

Collagen Matrix's new Collagen Dental Membrane granted FDA 510(k) clearance

After McDonald's flap, White House says it will exercise 'discretion' on medical loss ratios

LSUHSC-S receives $3.9M NIDA grant to develop EMB-001 drug for cocaine dependence

USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

MedQuist enters into definitive agreements for $310 million financing

Benicar better than Cozaar in reducing blood pressure: Study

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Chelsea prices common stock public offering

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News